



UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press Release

For immediate release

UCB ANNOUNCES POSITIVE NEW PRODUCTS RESULTS

December 2nd, 2004 - UCB, a leading biopharmaceutical company, informed on three new positive developments in its Research and Development pipeline during an analysts and investors meeting hosted today.

In neurology:

- Brivaracetam (ucb 34714), a high-affinity SV2A ligand targeting neurological diseases including epilepsy, has been evaluated in a first Phase II study including patients with photosensitive epilepsy. These results will be presented at the American Epilepsy Society meeting on December 6th. The outcome of this study shows that brivaracetam provided a more potent and complete seizure suppression in these patients than shown previously in studies with Keppra, UCB's marketed anti-epileptic drug in Europe and US. This confirms the potential and broad anti-epileptic potential of the family of SV2A ligands.

- Seletacetam (ucb 44212), another high-affinity SV2A ligand has completed its first Phase I study in healthy volunteers demonstrating a high tolerability and optimal PK profile. Phase II studies in epilepsy patients are planned and will be initiated early next year.

In inflammation:

- CDP323, an oral α 4-integrin inhibitor, has successfully completed a second Phase I multiple-dose study in healthy volunteers. Good plasma exposure and potent and prolonged inhibition of ligand binding to α 4-integrins in an vitro whole blood assay were demonstrated. This confirms CDP323's anti-inflammatory potential in diseases such as multiple sclerosis.

The documents from today's web cast *Business Review Meeting* are accessible using the following web address: <http://ir.ucb-group.com>

About the UCB Group

UCB (www.ucb-group.com) is a global pharmaceutical and specialty chemical leader with headquarters in Brussels, Belgium. Through its Pharma division, the company is focused on innovative solutions for human healthcare. UCB Pharma is a global biopharmaceutical leader, specialising in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. UCB Pharma's key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator) and Tussionex® (antitussive). UCB Pharma employs over 8,000 people operating in over 100 countries and, in 2003, achieved sales of €1.5 billion. UCB is listed on Euronext Brussels, and achieved sales of €3 billion and a net profit of €340 million in 2003.

On October 1st, 2004, UCB announced the sale of its Surface Specialties business, representing 4,500 people, to enable the Company to focus on its biopharmaceutical activities.

Information:

UCB - Press contacts

Laurence Battaille
Head of Corporate Communication
Tel.: +32 (2) 559 95 88

UCB – Investor Relations contacts

Arnaud Denis
Investor Relations Manager
Tel.: +32 (2) 559 92 64